Investigation of 4-methyl-2.2-dioxo-1h-2λ6,1-benzothiazine-3-carboxamide derivative influence on the biochemical markers of gastric mucosa in rats

  • О. V. Malchenko National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • N. І. Voloshchuk National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • N. O. Pentiuk National Pirogov Memorial Medical University, Vinnytsya, Ukraine
Keywords: N-(4-methoxybenzyl)-4-methyl-2,2-dioxo-1H-2λ6,1-benzothiazine-3-carboxamide, ulcerogenic effect, gastric mucosa, biochemical markers, oxidative stress, nitrogen monoxide, hydrogen sulfide.


Non-steroidal anti-inflammatory drugs occupy a leading position in the pharmaceutical market, but their class-specific side effect (ulcerogenic action) significantly limits their widespread use. The N-(4-methoxybenzyl)-4-methyl-2,2-dioxo-1H-2λ6,1-benzothiazine-3-carboxamide derivative (compound NI-9) showed a pronounced analgesic effect in various models of pain syndromes. The aim of the study was to determine the effect of a new original derivative of 4-methyl-2.2-dixo-1H-2λ6,1-benzothiazine-3-carboxylic acid on the macroscopic state and biochemical parameters of the gastric mucosa of rats. The study was performed on 51 male Wistar rats. Compound NI-9 and the reference drug meloxicam were administered intragastrically once daily for 28 days at doses of 3 and 5 mg/kg, corresponding to their ED50 analgesic activity. Macroscopic indicators of GM damage, glycosaminoglycan content, phospholipid profile, level of MDA and CGP, as well as nitrates and nitrites and H2S were determined. The results were processed in the program STATISTICA 10.0 using non-parametric methods. The results showed that the carboxamide derivative was safer for the stomach because the ulcer index of compound NI-9 was 1.73 times lower than that of meloxicam. The damaging effect of the compound was more pronounced at the pre-epithelial and epithelial levels of GM protection, while the post-epithelial level (production of vasodilating molecules NO and H2S) was practically unaffected by this derivative, unlike meloxicam, which caused damage at all levels of protection. The obtained data supplement the data on the pharmacodynamics of the 4-methyl-2.2-dixo-1H-2λ6,1-benzothiazine-3-carboxylic acid derivative and determine the expediency of its further studies as a potential non-opioid analgesic.


[1] Blackler, R., Bolla, M., Syer, S. Bolla, M., Ongini, E., & Wallace, J. L. (2012). Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence. PLoS One, 7(4), e35196. doi: 10.1371/journal.pone.0035196
[2] Bondarenko, О. О., Ahibalov, О. М. Dyadik, О.  О., & Steshenko, А.  О. (2020). Особливості ведення хворих з НПЗП-індукованою гастропатією: від розуміння механізмів розвитку до стратегії профілактики та лікування. Ризики короткочасного застосування нестероїдних протизапальних препаратів. Частина I [Feachures of management of patients with NSAID-induced gastropathy: from understanding the mechanisms of development to the strategy of prevention and treatment. Risks of short-term use of nonsteroidal anti-inflammatory drugs. Part I]. Сучасна гастроентерологія – Modern gastroenterology, (4), 39-50. doi: 10.30978/MG-2020-4-39
[3] Burukoglu, D., Baycu, C., Taplamacioglu, F., Sahin, E., & Bektur, E. (2016). Effects of nonsteroidal anti-inflammatory meloxicam on stomach, kidney, and liver of rats. Toxicol Ind Health., 32(6), 980-986. doi: 10.1177/0748233714538484
[4] Chan, M. V., & Wallace, J. L. (2013). Hydrogen sulfide-based therapeutics and gastrointestinal diseases: translating physiology to treatments. Am. J. Physiol. Gastrointest. Liver Physiol, 305(7), G467-473. doi: 10.1152/ajpgi.00169.2013
[5] Fidahic, M., Kadic, A. J., Radic, M. & Puljak, L. (2017). Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev, 6(6), CD012095. doi: 10.1002/14651858.CD012095.pub2
[6] García-Rayado, G., Navarro, M., & Lanas, A. (2018). NSAID induced gastrointestinal damage and designing GI-sparing NSAIDs. Expert. Rev. Clin. Pharmacol, (10), 1031-1043. doi: 10.1080/17512433.2018.1516143
[7] Hunt, R., Lazebnik, L. B, Marakhouski, Y. C., Manuc, M., Gn, R., Aye, K. S., … & Garg, A. (2018). International Consensus on Guiding Recommendations for Management of Patients with Nonsteroidal Antiinflammatory Drugs Induced Gastropathy-ICON-G. Euroasian Journal of Hepato-Gastroenterology, 8(2), 148-151. doi: 10.5005/jp-journals-10018-1281
[8] Keitz, М. (1975). Техника липидологии [Technique of lipidology]. М.: Мир – M.: Mir.
[9] Kleemann, A., Engel, J., Kutscher, B., & Reichert, D. (2008). Pharmaceutical Substances: Syntheses, Patents, Applications of the Most Relevant APIs, 5th ed. Thieme: Stuttgart, Germany.
[10] Kochetov, G. А. (1980). Практическое руководство по энзимологии [A practival guide to enzymology]. М.: Высшая школа – M.: Vishshaya shkola.
[11] Korenman, I. M. (1975). Методы определения органических соединений [Methods for determination of organic compounds]. М.: Химия – M.: Himia.
[12] Kuznetsov, S. G., Chigareva, S. M., & Ramsh, S. M. (1981). Prodrugs. Chemical aspect. Results Sci. Technol. VINITI. Ser. Org. Chem, (19), 1-176.
[13] Lowicka, E., & Bełtowski, J. (2007). Hydrogen sulfide (H2S) – the third gas of interest for pharmacologists. Pharmacological reports, (59), 4-24.
[14] Ludowieg, J., & Benmaman, D. (1967). Colorimetric differentiation of hexosamines. Anal. Biochem., 19(1), 80-88.
[15] Moore, R. A., Derry, S., Phillips, C. J., & McQuay, H. J. (2006). Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskeletal Disorders, (7), 79-91. doi: 10.1186/1471-2474-7-79
[16] O’Neil, M. J., Heckelman, P. E.; Koch, C. B., & Roman, K. J. (2006). The Merck Index:  An Encyclopedia of Chemicals, Drugs, and Biologicals, 14th ed. Merck and Co., Inc.:  Whitehouse Station, NJ, USA.
[17] Palileo, C., & Kaunitz, J. D. (2011). Gastrointestinal defense mechanisms. Curr. Opin. Gastroenterol., 27(6), 543-548. doi: 10.1097/MOG.0b013e32834b3fcb
[18] Proschak, E., Heitel, P., Kalinowsky, L., & Merk, D. (2017). Opportunities and challenges for fatty acid mimetics in drug discovery. J. Med. Chem, (60), 5235-5266. doi: 10.1021/acs.jmedchem.6b01287
[19] Stefanov, O. V. (red). (2001). Доклінічні дослідження лікарських засобів: Метод. рекомендації [Preclinical studies of drugs: Method. Recommendations]. K.: VD «Avitsena».
[20] Shevchuk, S. V., Pentuk, О. О., Musin, R. А., & Zaichko, N. V. (2003). Патент України 58110А [Patent of Ukraine 58110А]. Київ: державне патентне видавництво – Kyiv: State Patent Publishing House.
[21] Ukrainets, I. V., Hamza, G. M., Burian, A. A., Voloshchuk, N. I., Malchenko, O. V., Shishkina, S. V., … & Sim, G. (2018). Molecular Conformations and Biological Activity of N-Hetaryl(aryl)alkyl-4-methyl-2,2-dioxo-1H-2λ6,1-benzothiazine-3-carboxamides. Sci. Pharm, (86), 50. doi: 10.3390/scipharm86040050
[22] Ukrainets, I. V., Mospanova, E. V., Savchenkova, L. V., & Yankovich, S. I. (2011). 4-Hydroxy-2-quinolones. 195. Synthesis of novel, potential analgesics based on 4-(hetarylmethyl)amino-2-oxo-1,2-dihydroquinoline-3-carboxylic acids. Chem. Heterocycl. Compd., (47), 67-73.
[23] Vladimirov, Yu. А., & Archakov А. I. (1972). Перекисное окисление липидов в биологических мембранах [Lipid peroxidation in biological membranes]. М.: Наука – M.: Nauka.
[24] Voloshchuk, N., Taran, I., Pashynska, O., Melnyk, A., & Magdebura, S. (2020). The role of hydrogen sulfide in gastrointestinal tract functioning. Current Issues in Pharmacy and Medical Sciences, 1(33), 45-50. doi: 10.2478/cipms-2020-0009
[25] Voloshchuk, N. I., Taran, I. V., & Mel’nik, A. V. (2015). Influence of diclofenac sodium on biochemical indicators of stomach mucosa conditions against the background of excess and deficiency of hydrogen sulfide in rats. The Science Advanced, (01), 36-40.
[26] Voloshchuk, N. I., Taran, I. V., & Mel’nik, A. V. (2015). Vascular mechanism in the diclophenac induced gastrotoxicity: the association with the level of hydrogen sulfide. Curierul medical, 58(1), 7-11.
[27] Victorov, О. P. & Kashuba, О. V. (2010). Проблеми та перспективи отримання інформації пропобічні реакції, спричинені нестероїдними протизапальними препаратами, шляхом анонімного опитування пацієнтів (погляд на проблему) [Problems and prospects of obtaining information on side effects caused by nonsteroidal anti-inflammatory drugs by anonymous survey of patients (view of the problem)]. Український медичний часопис – Ukrainian medical journal, 6(80), 111-114.
[28] Wallace J. L., Vaughan, D., Dicay, M., MacNaughton, W. K., & de Nucci, G. (2018). Hydrogen Sulfide-Releasing Therapeutics: Translation to the Clinic. Antioxid Redox Signal, 28(16), 533-1540. doi: 10.1089/ars.2017.7068
[29] Zaichko, N. V., Pentuk, N. О., & Melnyk, А. V. (2010). Патент України 52136 [Patent of Ukraine 52136]. Київ: державне патентне видавництво – Київ: державне патентне видавництво.
How to Cite
MalchenkoО. V., VoloshchukN. І., & Pentiuk, N. O. (2020). Investigation of 4-methyl-2.2-dioxo-1h-2λ6,1-benzothiazine-3-carboxamide derivative influence on the biochemical markers of gastric mucosa in rats. Biomedical and Biosocial Anthropology, (41), 36-40.